top of page
Scientist working in the laboratory



Collaboration with pharmaceutical companies is a significant part of our mission.


Those are at the forefront of research and treatment of MPN and therefore directly impact the lives of all patients.

Our initiatives support the pharmaceutical industry in various aspects.

Swift Synergy

Faster communications and cooperations between industry and the patient community to improve the quality of care and research.

Feedback & Guidance

Provide feedback and guidance on developing and implementing new treatments and clinical trials.

Awareness Boost

Raise awareness and educate about the MPN among health professionals, polycymakers and the public.

MPN Impact

Making a difference in the MPN field, improving MPN patients live.

Patient Testimonials

Giving voice to patients with MPN and shareing their stories and struggles at different phases of their journey and therapy.

MPN Dialogues

We foster engaging discussions on MPN-related topics by hosting and promoting webinars, seminars, and roundtables.

Our MPN Awareness Partners



We find answers that make life better for patients and our world.
Abbvie logo

Since our launch in 2013, we have invested ~$50 billion in research to discover, develop and deliver new medicines. We target diseases with significant unmet need where we can improve the standard of care with innovative new therapies. We’re constantly working to create solutions that go beyond treating the illness to have a positive impact on patients’ lives, on societies—and on science itself. Today, our ~50,000 employees around the world focus on discovering and delivering transformational medicines and products in several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, and women’s health, as well as through our Allergan Aesthetics portfolio. We care deeply for patients and customers, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. We embrace diverse backgrounds and perspectives and treat everyone equally, with dignity and respect, allowing us all to achieve our best. 




AOP Health

Targeting Rare Diseases and Critical Care
AOP Health Logo

AOP Health is the European pioneer for integrated therapies for rare diseases and in critical care. AOP Orphan – now AOP Health – was founded in 1996 by Dr. Rudolf Widmann with the aim of developing and providing therapy options for patients with rare diseases, and then introducing the therapy options first in Austria, the European core countries of AOP Health, and finally in the international market.  Thanks to our advancements in the field of therapies, an increasing number of patients survive their disease or are able to live with it for a longer period of time. In the next few decades, personalized medicine, individual treatment opportunities will emerge more and more as the standard in AOP Health’s therapy concepts as well.



Bristol Meyers Squibb

Global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
BMS Logo

At Bristol Myers Squibb, we believe in the power of science to address some of the most challenging diseases of our time. Our focus on these unmet needs comes during a remarkable time, when unprecedented scientific breakthroughs are advancing the treatment of disease as never before in human history. We work every day to transform patients’ lives through science. Each day, our employees around the world work together for patients – they are at the center of everything we do. They inspire us. They are the reason we come to work each day. We combine the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation. We are proud of the advancements we have made in oncology, hematology, immunology and cardiovascular disease, and we are dedicated to helping patients prevail over serious diseases through our diverse and promising pipeline and new scientific platforms.

As global citizens, we work sustainably and responsibly to create a positive impact in the communities where we live and work. We conduct our global business with the utmost integrity and transparency. We support programs, initiatives and organizations that help improve health, expand research opportunities, promote and expand STEM education and deliver basic human services to our communities.




We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.
GSK Logo

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.

We aim to positively impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance.

We are a company where outstanding people can thrive.

GSK has changed. In July 2022, we demerged our world-leading consumer healthcare business, Haleon. We are now a fully focused biopharma company. We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.



Kartos Therapeutics

Dedicated to the development of novel, targeted therapeutics that meaningfully improve the lives of patients with cancer
Kartos Therapeutics Logo

Kartos Therapeutics is a privately held, clinical-stage biopharmaceutical company developing a potentially best-in-class MDM2 inhibitor. Launched in 2018 by proven industry veterans, we are a passionate team based in Redwood City, California, and Bellevue, Washington.

We have brought together scientists and clinicians with a deep understanding of hematology and oncology and an experienced leadership team. Together, we’re building an exciting biotechnology company with a culture defined by caring, ambition, dedication, and teamwork!




Dedicated to the development of novel, targeted therapeutics that meaningfully improve the lives of patients with cancer
Morphosys Logo

MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. Our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical company, we are driven by the urgency to deliver groundbreaking medicines, aspiring to give more life for people with cancer. Our values guide us in the decisions we make each day. They shape our commitment to one another and society – underscoring our collective responsibility to operate with the highest level of integrity, respect and quality standards. We are conscious of the responsibility we share for present and future generations and weigh all our actions in terms of their impact on the environment, society, patients and employees. Advancing science is at our core, but even more so is our dedication to make a difference for patients.




We use the power of leading-edge science to save and improve lives around the world

For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.

Merck has acquired Imago BioSciences, a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases. Merck’s acquisition of Imago augments its pipeline and strengthens its presence in the growing field of hematology. 



Protagonist Therapeutics

We strive to improve patients’ lives through the power of peptide drug discovery and development, targeting areas of unmet need across rare and prevalent diseases where treatments are limited or inadequate.
Protagonist Therapeutics Logo

Welcome to Protagonist, a clinical-stage biopharmaceutical company poised to deliver life-changing therapies. At Protagonist, we strive to improve patients’ lives through the power of drug discovery and development, targeting areas of unmet need across rare and prevalent diseases where treatments are limited or inadequate. Protagonist is a clinical-stage biopharmaceutical company committed to developing novel peptide-based drugs to address significant unmet medical needs and making them available broadly to patients as quickly as possible by conducting the clinical trials necessary to gain approval by regulatory authorities. We have five novel peptidic assets currently in different stages of clinical studies. Rusfertide (PTG-300) is a hepcidin mimetic currently being studied as a treatment for polycythemia vera (PV) and hereditary hemochromatosis (HH). PN-943 is an α4β7 integrin-specific antagonist being studied in patients with moderate-to-severely active ulcerative colitis (UC). In October 2020, we announced the selection of two second-generation IL-R antagonists for advancement into clinical development, PN-235 (also referenced as JNJ-77242113) and PN-232 (also referenced as JNJ-75105186)



Opinion Health

Quality Research Solutions
Opinion Health Logo

Opinion Health is a research company that helps organizations in planning, implementing and executing strategic healthcare business decisions by putting patients and key healthcare stakeholders at the core of research. They have more than 50 years of experience conducting market research around the globe for major pharmaceutical and healthcare companies. They provide their clients with actionable, cost-effective and quality input to their strategy, marketing and product decisions. They have on-staff medical advisers and a multi-lingual and multi-cultural team. They have built panels of patients suffering from both high and some very low prevalence diseases and added these to their panels of healthcare professionals and other decision makers. They use primary and secondary research and investigation methods to resolve any problems related to multi-disciplinary teams. They have developed their Social Media Disease Monitor which allows clients to measure the pulse of their current and target patients and what they are saying about their and their competitors’ products. They form a true partnership with their clients from initial discussions about a potential project through to the final delivery of the findings and their integration into action plans.


bottom of page